Washington, DC, United States of America

Thomas S Uldrick


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas S. Uldrick: Innovator in Cancer Treatment

Introduction

Thomas S. Uldrick is a notable inventor based in Washington, DC, who has made significant contributions to the field of oncology. His work primarily focuses on the treatment of Kaposi's sarcoma and KSHV-induced lymphoma, utilizing innovative immunomodulatory compounds. Uldrick's research has the potential to improve patient outcomes and provide new avenues for treatment.

Latest Patents

Uldrick holds a patent titled "Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers." This patent outlines the use of gene and protein biomarkers as predictors of clinical sensitivity to treatment for Kaposi's sarcoma and KSHV-induced lymphoma. It also details methods for managing these conditions with immunomodulatory compounds, either alone or in combination with doxorubicin.

Career Highlights

Throughout his career, Uldrick has worked with prominent organizations such as Celgene Corporation and the National Institutes of Health, which is a component of the US Department of Health & Human Services. His experience in these institutions has allowed him to contribute to groundbreaking research in cancer treatment.

Collaborations

Uldrick has collaborated with esteemed colleagues, including Robert Yarchoan and Jerome B. Zeldis. These partnerships have furthered his research and expanded the impact of his work in the medical community.

Conclusion

Thomas S. Uldrick's innovative approach to treating Kaposi's sarcoma and KSHV-induced lymphoma highlights his dedication to improving cancer therapies. His contributions through patents and collaborations continue to influence the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…